Last reviewed · How we verify
EM-100
EM-100 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation.
EM-100 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation. Used for Corneal neovascularization, Corneal scarring and opacity.
At a glance
| Generic name | EM-100 |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Wnt/β-catenin pathway inhibitor |
| Target | Wnt/β-catenin signaling pathway |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
EM-100 targets the Wnt signaling cascade, which plays a key role in pathological corneal neovascularization and inflammatory responses in the eye. By inhibiting this pathway, the drug aims to suppress abnormal blood vessel growth and reduce corneal opacity and inflammation associated with various corneal conditions.
Approved indications
- Corneal neovascularization
- Corneal scarring and opacity
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EM-100 CI brief — competitive landscape report
- EM-100 updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI